Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas

E. M. Hartenbach, T. A. Olson, J. J. Goswitz, D. Mohanraj, L. B. Twiggs, L. F. Carson, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalCancer Letters
Volume121
Issue number2
DOIs
StatePublished - Dec 23 1997
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Carcinoma
Survival
Microvessels
Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
von Willebrand Factor
Survival Analysis
Antibodies

Keywords

  • Angiogenesis
  • Ovarian cancer
  • Vascular permeability factor
  • VPF

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. / Hartenbach, E. M.; Olson, T. A.; Goswitz, J. J.; Mohanraj, D.; Twiggs, L. B.; Carson, L. F.; Ramakrishnan, Sundaram.

In: Cancer Letters, Vol. 121, No. 2, 23.12.1997, p. 169-175.

Research output: Contribution to journalArticle

Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Letters. 1997 Dec 23;121(2):169-175. https://doi.org/10.1016/S0304-3835(97)00350-9
Hartenbach, E. M. ; Olson, T. A. ; Goswitz, J. J. ; Mohanraj, D. ; Twiggs, L. B. ; Carson, L. F. ; Ramakrishnan, Sundaram. / Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. In: Cancer Letters. 1997 ; Vol. 121, No. 2. pp. 169-175.
@article{82d7a019f6064f23bb5aa6c71e3c4a47,
title = "Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas",
abstract = "Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.",
keywords = "Angiogenesis, Ovarian cancer, Vascular permeability factor, VPF",
author = "Hartenbach, {E. M.} and Olson, {T. A.} and Goswitz, {J. J.} and D. Mohanraj and Twiggs, {L. B.} and Carson, {L. F.} and Sundaram Ramakrishnan",
year = "1997",
month = "12",
day = "23",
doi = "10.1016/S0304-3835(97)00350-9",
language = "English",
volume = "121",
pages = "169--175",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas

AU - Hartenbach, E. M.

AU - Olson, T. A.

AU - Goswitz, J. J.

AU - Mohanraj, D.

AU - Twiggs, L. B.

AU - Carson, L. F.

AU - Ramakrishnan, Sundaram

PY - 1997/12/23

Y1 - 1997/12/23

N2 - Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.

AB - Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.

KW - Angiogenesis

KW - Ovarian cancer

KW - Vascular permeability factor

KW - VPF

UR - http://www.scopus.com/inward/record.url?scp=0031455936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031455936&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(97)00350-9

DO - 10.1016/S0304-3835(97)00350-9

M3 - Article

C2 - 9570355

AN - SCOPUS:0031455936

VL - 121

SP - 169

EP - 175

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -